Lifastuzumab vedotin
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized (from mouse) |
Target | phosphate-sodium cotransporter |
Clinical data | |
Other names | DNIB0600A |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6504H10028N1744O2018S46 |
Molar mass | 146416.72 g·mol−1 |
Lifastuzumab vedotin (INN;[1] development code DNIB0600A) is an experimental monoclonal antibody-drug conjugate designed for the treatment of cancer.[2]
This drug was developed by Genentech/Roche.
References
Categories:
- Articles with short description
- Short description is different from Wikidata
- Drugs not assigned an ATC code
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- All stub articles
- Monoclonal antibody stubs
- Experimental cancer drugs
- Monoclonal antibodies for tumors
- Antibody-drug conjugates